8-K: Relay Therapeutics Q2 2025 Results & Phase 3 Trial Update

Relay Therapeutics reported second quarter 2025 financial results, highlighted by the initiation of its Phase 3 ReDiscover-2 trial and consistent RLY-2608 clinical data.

Summary

• Relay Therapeutics announced its financial results for the second quarter ended June 30, 2025.
• The company initiated its Phase 3 ReDiscover-2 trial for RLY-2608 + fulvestrant in HR+/HER2breast cancer patients.
• Updated interim clinical data from the Phase 1b study for RLY-2608 + fulvestrant showed consistency with previous disclosures, including a 10.3-month median progression-free survival (PFS) and 39% objective response rate (ORR) across all patients with PI3K-mutated, HR+/HER2metastatic breast cancer.
• For second-line (2L) patients, the median PFS was 11.0 months, with 18.4 months for patients with kinase mutations and 8.5 months for patients with non-kinase mutations, and a 42% confirmed ORR.
• The safety profile of RLY-2608 remained strong with mostly low-grade treatment-related adverse events.
• Cash, cash equivalents, and investments totaled $656.8 million as of June 30, 2025, down from $710.4 million as of March 31, 2025.
• The company expects its current cash, cash equivalents, and investments to fund operations into 2029.
• Revenue for Q2 2025 was $0.7 million, compared to $0 for Q2 2024.
• Research and development (R&D) expenses decreased to $63.9 million in Q2 2025 from $92.0 million in Q2 2024, primarily due to strategic streamlining and cost avoidance.
• General and administrative (G&A) expenses decreased to $13.6 million in Q2 2025 from $20.1 million in Q2 2024, mainly due to reduced stock compensation and employee compensation costs.
• Net loss for Q2 2025 was $70.4 million, or $0.41 per share, an improvement from a net loss of $92.2 million, or $0.69 per share, in Q2 2024.

Sentiment

Score: 8

Explanation: The filing indicates strong progress in clinical development with the initiation of a Phase 3 trial and consistent positive interim data for RLY-2608. Financial results show improved efficiency with reduced losses and an extended cash runway, which are all positive indicators for a clinical-stage biotech company.

Positives

• Initiation of the pivotal Phase 3 ReDiscover-2 trial for RLY-2608, marking a significant advancement in the clinical development of the lead asset.
• Consistent and positive interim Phase 1b clinical data for RLY-2608, demonstrating a 10.3-month median PFS and 39% ORR, which management believes shows potential benefits compared to historical standard of care.
• Strong safety profile for RLY-2608 with predominantly low-grade treatment-related adverse events.
• Extended cash runway into 2029, providing financial stability and sufficient capital for ongoing operations and clinical programs.
• Significant reduction in Research and Development (R&D) expenses by $28.1 million year-over-year, reflecting successful strategic streamlining and cost avoidance.
• Decrease in General and Administrative (G&A) expenses by $6.5 million year-over-year, indicating improved operational efficiency.
• Reduced net loss to $70.4 million in Q2 2025 from $92.2 million in Q2 2024, demonstrating improved financial performance.

Negatives

• Continued net loss of $70.4 million for the quarter, indicating the company is still in a development phase and not yet profitable.
• Cash, cash equivalents, and investments decreased by $53.6 million from $710.4 million at the end of Q1 2025 to $656.8 million at the end of Q2 2025.

Risks

• Restructuring activities may be more costly or time-consuming than expected or may not achieve their intended results.
• The expected decrease in annual spending may not materialize as anticipated.
• Existing cash resources may not be sufficient if internal and external costs for ongoing and planned activities are higher than expected, potentially leading to faster cash burn or changes/curtailment of plans.
• Global economic uncertainty, geopolitical instability, conflicts, or public health epidemics could impact operations, clinical trials, strategy, and profitability.
• Significant political, trade, or regulatory developments beyond the company's control could adversely affect the business.
• There is a risk of delay or pause in any current or planned clinical trials or the development of drug candidates.
• Preliminary or interim results of preclinical or clinical trials, including the Phase 3 ReDiscover-2 trial, may not be predictive of future or final results, and interim data may change as more patient data become available.
• The design and rate of enrollment for current clinical trials may not enable successful completion of the trial(s).
• The company's ability to successfully demonstrate the safety and efficacy of its drug candidates is not guaranteed.
• The timing and outcome of planned interactions with regulatory authorities are uncertain.
• Obtaining, maintaining, and protecting intellectual property rights is crucial and subject to risks.

Future Outlook

The company expects its current cash, cash equivalents, and investments to be sufficient to fund its operating expenses and capital expenditure requirements into 2029. The top priority is to enroll patients and execute the Phase 3 ReDiscover-2 trial, with the aim of delivering a novel medicine in the post-CDK4/6 breast cancer setting where there is a large unmet medical need.

Management Comments

• "It is an exciting time for Relay as we have initiated our Phase 3 ReDiscover-2 Trial, studying RLY-2608 + fulvestrant versus capivasertib + fulvestrant in HR+/HER2breast cancer patients." Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.
• "The interim data from our Phase 1 trial have remained consistent with previously announced data, showing what we believe are the potential benefits of RLY-2608 compared to historical standard of care data for both safety and efficacy." Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.
• "It is our company's top priority to enroll patients and execute this trial, and hopefully deliver a novel medicine in the post-CDK4/6 breast cancer setting where there is a large unmet medical need." Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.

Industry Context

Relay Therapeutics operates in the highly innovative and competitive precision medicine sector, focusing on small molecule therapies for oncology and genetic diseases. The initiation of a Phase 3 trial for RLY-2608 in HR+/HER2metastatic breast cancer addresses a critical unmet medical need in patients who have progressed after CDK4/6 inhibitors, a significant patient population. The company's Dynamo platform, which integrates computational and experimental approaches to drug previously intractable protein targets, positions it as a key player in developing next-generation therapies within the pharmaceutical and biotechnology industry.

Comparison to Industry Standards

• RLY-2608's Phase 1b data, including a 10.3-month median PFS and 39% ORR, is presented as consistent with prior disclosures and showing potential benefits compared to 'historical standard of care data' for PI3K-mutated, HR+/HER2metastatic breast cancer.
• The Phase 3 ReDiscover-2 trial is designed to compare RLY-2608 + fulvestrant against capivasertib + fulvestrant, indicating capivasertib as a relevant benchmark or competitor in the treatment landscape for HR+/HER2breast cancer patients who have been pre-treated with CDK4/6 inhibitors.

Stakeholder Impact

• Shareholders: Positive impact due to the advancement of the lead asset (RLY-2608) into a pivotal Phase 3 trial, consistent positive clinical data, improved financial efficiency (reduced losses and expenses), and an extended cash runway, which collectively de-risk the investment.
• Patients: Potential for a novel and effective treatment (RLY-2608) for PI3K-mutated, HR+/HER2metastatic breast cancer, addressing a significant unmet medical need in the post-CDK4/6 setting.
• Employees: The strategic choices to streamline the research organization in 2024 and 2025 suggest past workforce adjustments, but the current focus on executing the Phase 3 trial indicates a clear strategic direction for the remaining team.

Next Steps

• Enroll patients and execute the Phase 3 ReDiscover-2 trial for RLY-2608 + fulvestrant in PI3K-mutated, CDK4/6 pre-treated, HR+/HER2advanced breast cancer.
• Continue advancement of the ongoing triplet cohorts with RLY-2608 + fulvestrant + atirmociclib or ribociclib.
• Continue execution of the ongoing Phase 1 vascular malformations clinical trial.

Key Dates

Recommendation

The initiation of a pivotal Phase 3 trial for RLY-2608, coupled with consistent and promising Phase 1b clinical data that appears to outperform historical standard of care, significantly de-risks the lead asset. The company's improved financial discipline, evidenced by reduced R&D and G&A expenses and an extended cash runway into 2029, provides a solid foundation for executing this critical trial. This progress positions Relay Therapeutics favorably in the competitive oncology landscape, making it an attractive investment for long-term growth.

Keywords

Precision medicine, Oncology, Breast cancer, PI3K inhibitor, RLY-2608, Clinical trial, Phase 3, Drug development, Biotechnology, Cancer therapy, Genetic disease, Financial results